By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


SEARCH JOBS


Industry
Biotechnology






Company News
BioMarin (BMRN) Announces FDA Accepts Drisapersen NDA For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 6/29/2015 7:33:23 AM
BioMarin (BMRN) Announces European Medicines Agency Validates MAA For Drisapersen For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 6/26/2015 6:31:15 AM
BioMarin (BMRN) Surging on Impressive Phase II Dwarfism Data 6/18/2015 6:32:43 AM
BioMarin (BMRN) CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year 2015 Award In Northern California In Health And Life Sciences 6/15/2015 9:10:12 AM
Alexion (ALXN), BioMarin (BMRN), Sanofi (SAN.PA), Shire (SHPGY) May Be Eyeing Dyax Corp. (DYAX) and Its Rare Genetic Disorder Drug 6/11/2015 6:27:19 AM
BioMarin (BMRN) Submits Drisapersen MAA To European Medicines Agency For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 6/8/2015 7:58:53 AM
Jean-Jacques Bienaime, CEO Of BioMarin (BMRN), To Present At The Goldman, Sachs & Co. 36th Annual Global Healthcare Conference 6/5/2015 7:26:31 AM
BioMarin (BMRN) Management To Present At The Deutsche Bank (DB) 40th Annual Health Care Conference On May 6th; Bank of America (BAC) Merrill Lynch 2015 Health Care Conference On May 13th; And, The UBS Global Healthcare Conference On May 19th 5/1/2015 10:21:39 AM
BioMarin (BMRN) Announces First Quarter 2015 Financial Results And Company Update 5/1/2015 8:35:08 AM
BioMarin (BMRN) Completes Rolling NDA Submission To FDA For Drisapersen For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 4/27/2015 7:52:06 AM
12345678910...
//-->